Abstracts tagged "Biomarkers"

Abstract Number: 2557 • 2013 ACR/ARHP Annual Meeting
Fluctuations In sVCAM-1 and Adiponectin Mirror Fluctuations In Disease Activity In Lupus, But Cannot Be Use To Accurately Predict Impending Changes In Disease State
Carolina landolt-Marticorena¹, Stephenie Prokopec², Stacey Morrison³, Heather Reich⁴, James Scholey⁴, Dafna D. Gladman⁵, Murray B. Urowitz⁵, Paul Boutros², Paul R. Fortin⁶ and Joan E. Wither⁷, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Ontario Institute for Cancer Research, Toronto, ON, Canada, ³Div Rheumatology Rm MP-10-304, The Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Medicine, The Toronto Western Hospital, Toronto, ON, Canada, ⁵Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶University of Laval, Quebec, QC, Canada, ⁷1E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Previous reports have identified a number of pro-inflammatory cyto/chemokines as candidate activity-specific SLE biomarkers. In our preliminary studies we found that out of a…
Abstract Number: 1974 • 2013 ACR/ARHP Annual Meeting
Assessing Validity Of Low Field Magnetic Resonance Imaging (MRI) for Joint Inflammation and Damage In Wrist/Hand Rheumatoid Arthritis (RA) – A Systematic Literature Review (SLR)
OM Troum¹, OL Pimienta¹, TG Woodworth², O Morgacheva³, V Ranganath⁴ and Daniel Furst⁵, ¹Keck School of Medicine, University of Southern California, Los Angeles, CA, ²Medicine, Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, CA, ³Medicine/Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, CA, ⁴Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁵David Geffen School of Medicine, University of California, Los Angeles, CA
Background/Purpose: Radiographic scoring of erosions and joint space narrowing (JSN) of the hand/wrist is standard to evaluate RA joint damage for regulatory approval of DMARDs;…
Abstract Number: 1388 • 2013 ACR/ARHP Annual Meeting
Multiplex Cytokine Analyses In Patients With Rheumatoid Arthritis Require Use Of Agents Blocking Heterophilic Antibody Activity
Peter Olsson¹, Elke Theander², Ulf Bergström³, Stefan Jovinge⁴, Lennart Jacobsson³ and Carl Turesson², ¹Section of Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden, ²Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University, Lund, Sweden
Background/Purpose: Rheumatoid factor (RF) and other circulating heterophilic antibodies have been shown to interfere with antibody-based immunoassays, in particular with multiplex protein detection platforms. Previous…
Abstract Number: 524 • 2013 ACR/ARHP Annual Meeting
Expansion Of DC-STAMP⁺ IL-17⁺ Cells In Bone Marrow From Psoriasis and Psoriatic Arthritis Patients
Yahui Grace Chiu¹, Edward M. Schwarz², Jamie Biear¹, Debbie Campbell³, Jennifer Hossler¹, Jennifer H. Anolik⁴, R. John Looney¹ and Christopher T. Ritchlin¹, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ³Allergy, Immunology and Rheumatology, Univerity of Rochester, Rochester, NY, ⁴Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Focal erosions in inflammatory arthritis are mediated by bone marrow (BM) derived osteoclasts (OC) that enter the joint as OC precursors (OCP) from peripheral…
Abstract Number: 144 • 2013 ACR/ARHP Annual Meeting
Cytokines, Oxidative Stress Markers and Brain-Derived Neurotrophic Factor In Fibromyalgia Syndrome
Aline Ranzolin^1,2, Claudio Antônio da C. Neto³, Bruna Maria Ascoli⁴, Bianca Wollenhaupt-Aguiar⁵, Angela Luzia B. Pinto Duarte³, Markus Bredemeier⁶, Flávio Kapczinski⁴ and Ricardo M. Xavier⁷, ¹Rheumatology, Hospital das Clínicas - Universidade Federal de Pernambuco, Recife, Brazil, ²Programa de Pós-Graduação em Ciências Médicas da Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ³Faculdade de Medicina, Universidade Federal de Pernambuco - Hospital das Clínicas de Pernambuco, Recife, Brazil, ⁴Programa de Pós-Graduação em Ciências Médicas da Universidade Federal do Rio Grande do Sul: Psiquiatria, Porto Alegre, Brazil, ⁵Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, da Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁶Rheumatology, Hospital Nossa Senhora da Conceição - Grupo Hospitalar Conceição, Porto Alegre, Brazil, ⁷Rheumatology Division, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Background/Purpose: The pathophysiology of Fibromyalgia Syndrome (FMS) is incompletely understood. An imbalance of pro- and anti-inflammatory cytokines is assumed to play a role in the…
Abstract Number: 2566 • 2013 ACR/ARHP Annual Meeting
Nilotinib Treatment Effect In The Skin As Measured By DNA Microarray In Patients With Diffuse Systemic Sclerosis
Jessica K. Gordon¹, Tammara A. Wood², Robert F. Spiera¹ and Michael L. Whitfield², ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Gene expression profiling by DNA microarray is used to identify potential biomarkers in Systemic Sclerosis (SSc). Discrete gene expression signatures have been observed to…
Abstract Number: 1903 • 2013 ACR/ARHP Annual Meeting
PIK3CD Overexpression In The Synovial Membrane Of Rheumatoid Arthritis Patients Is Associated With Response To Anti-TNF Therapy
Antonio Julià¹, Gabriela Ávila¹, Raquel Celis², Raimon Sanmarti³, Julio Ramirez⁴, Sara Marsal¹ and Juan D. Cañete³, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Arthritis Unit, Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: The mechanisms by which Rheumatoid Arthritis (RA) patients do not respond to TNF blockade are still poorly characterized. The goal of this study is…
Abstract Number: 1345 • 2013 ACR/ARHP Annual Meeting
Retinal Vascular Calibre – a Novel Biomarker Of Inflammation and Treatment Response In Rheumatoid Arthritis
John HY Moi^1,2, Lauren AB Hodgson^3,4,5, Ian P Wicks^1,6,7, Tien Yin Wong^3,4,5,8 and Sharon Van Doornum^1,3,9, ¹Department of Rheumatology, The Royal Melbourne Hospital, Melbourne, Australia, ²Department of Medicine, The University of Melbourne, Melbourne, Australia, ³The University of Melbourne, Melbourne, Australia, ⁴Royal Victorian Eye and Ear Hospital, Melbourne, Australia, ⁵Centre for Eye Research Australia, Melbourne, Australia, ⁶Department of Medical Biology, University of Melbourne, Parkville, Australia, ⁷Inflammation Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Australia, ⁸Singapore Eye Research Institute, Singapore, Singapore, ⁹Melbourne EpiCentre, The Royal Melbourne Hospital, Melbourne, Australia
Background/Purpose: Retinal vascular calibre measurement is a non-invasive tool for assessing systemic and vascular health. Widened retinal venular calibre (RVC) is associated with systemic inflammation,…
Abstract Number: 444 • 2013 ACR/ARHP Annual Meeting
Reversibility Of Pharmacodynamic Effects After Short- and Long-Term Treatment With Tofacitinib In Patients With Rheumatoid Arthritis
M. C. Genovese¹, T. Kawabata², K. Soma², S. Menon², J.D. Clark³, J. Hodge⁴, L. Takiya⁴, R. Riese² and S. Krishnaswami⁵, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Cambridge, MA, ⁴Pfizer Inc, Collegeville, PA, ⁵Clinical Pharmacology, Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). It has a short pharmacokinetic (PK) half-life of…
Abstract Number: 149 • 2013 ACR/ARHP Annual Meeting
Comparative Proteomic Analysis Of Neutrophils From Patients With Microscopic Polyangiitis and Granulomatosis With Polyangiitis
Teisuke Uchida¹, Kohei Nagai², Toshiyuki Sato³, Nobuko Iizuka³, Mitsumi Arito³, Yukiko Takakuwa⁴, Hiromasa Nakano⁴, Seido Ooka⁴, Manae Kurokawa³, Naoya Suematsu³, Kazuki Okamoto³, Shoichi Ozaki⁵ and Tomohiro Kato³, ¹Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, kawasaki, Japan, ²Department of Genetic Engineering, Faculty of Biology-Oriented Science and Technology, Kinki University, Wakayama, Japan, ³Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine, Kawasaki, Japan, ⁴Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Both microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) belong to ANCA-associated vasculitis (AAV), in which neutrophils are thought to be involved in their…
Abstract Number: 2412 • 2013 ACR/ARHP Annual Meeting
Anti-CCP Antibodies and Increased Cartilage Turnover In Patients Developing Rheumatoid Arthritis
Carl Turesson¹, Christina Book², Ulf Bergström², Lennart Truedsson³, Lennart Jacobsson² and Tore Saxne⁴, ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden, ⁴Section of Rheumatology, Deparment of Clinical Sciences, Lund, Lund University, Lund, Sweden
Background/Purpose: Autoantibodies may be detected years before the onset of rheumatoid arthritis (RA). We have previously shown that levels of Cartilage oligomeric matrix protein (COMP),…
Abstract Number: 1869 • 2013 ACR/ARHP Annual Meeting
Serum Cytokine/Chemokine Profiles Are Useful For Evaluating Pathological Conditions Of Rheumatoid Arthritis and Diagnosing Anti-CCP Antibody-Negative Patients
Hitoshi Uga¹, Takahiro Okazawa¹, Yoshiaki Miyamoto¹, Takehiro Hasegawa¹, Jun Saegusa², Goh Tsuji³, Sho Sendo⁴, Akio Morinobu⁵, Shunichi Kumagai^6,7 and Hirokazu Kurata¹, ¹Sysmex Corporation, Kobe, Japan, ²Department of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, ³Center for Rheumatic Diseases, Shinko Hospital, Kobe, Japan, ⁴Center of rheumatic diseases, Shinko Hospital, Kobe, Japan, ⁵Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Center of rheumatic diseases, Shinko hospital, Kobe, Japan, ⁷Department of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: The diagnosis of anti-CCP antibody (ACPA) negative rheumatoid arthritis (RA) are known to be difficult and delayed as compared with ACPA-positive RA. This study…
Abstract Number: 1347 • 2013 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity Score For Rheumatoid Arthritis Predicts Radiographic Damage In The BeSt Study
I.M. Markusse¹, L. Dirven¹, M. van den Broek¹, K.H. Han², M.F. van Lieshout³, N. Riyazi⁴, R.J. Bolce⁵, E.H. Sasso⁵, P.J.S.M. Kerstens⁶, W.F. Lems⁷, T.W.J. Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Rheumatology, Spaarne Hospital, Hoofddorp, Netherlands, ⁴Rheumatology, Haga Hospital, The Hague, Netherlands, ⁵Crescendo Bioscience Inc., South San Francisco, CA, ⁶Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁷Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: To determine whether a multi-biomarker disease activity (MBDA) score could predict radiographic damage progression in patients with rheumatoid arthritis (RA). Methods: The BeSt study…
Abstract Number: 458 • 2013 ACR/ARHP Annual Meeting
High Levels Of Natural Killer CELLS ARE Associated With Response To Tocilizumab In Patients With Severe Rheumatoid Arthritis
Claire I. Daien^1,2, Sarah Gailhac³, Rachel Audo¹, Thibault Mura⁴, Michael Hahne¹, Bernard Combe⁵ and Jacques Morel⁶, ¹IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ²Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ³Igmm UMR3555, CNRS, Montpellier, France, ⁴CIC, Hopital Gui De Chauliac, Montpellier, France, ⁵Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁶Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: Inhibition of interleukin 6 (IL-6) receptor with tocilizumab (TCZ) is effective for rheumatoid arthritis (RA). However, the effect of TCZ on lymphocytes remains poorly…
Abstract Number: 156 • 2013 ACR/ARHP Annual Meeting
Cartilage Peptide Profiling: Identifying Novel OA Biomarkers For Early Disease Detection
Valentina Calamia¹, Lucía Lourido¹, Diego López¹, Jesus Mateos¹, Patricia Fernández-Puente¹, Carolina Fernández-Costa², Beatriz Rocha², Cristina Ruiz-Romero³ and Francisco J. Blanco¹, ¹Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain, ²Grupo de Proteomica-PBR2-ProteoRed/ISCIII-Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006., A Coruña, Spain, ³Grupo de Proteomica-PBR2-ProteoRed/ISCIII Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006 A Coruña, Spain, A Coruña, Spain
Background/Purpose: Cartilage secretome contains a complex matrix of proteolytically derived peptides that may provide useful information of the biological events occurring in the articular joint…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].